Gazyva

November 7, 2017November 7, 2017

Study Links Early Progression to Poorer Survival Outcomes in Follicular Lymphoma Patients

News

New data from the GALLIUM Phase 3 trial (NCT01332968) shows that follicular lymphoma patients who progress within two years of immunochemotherapy have a 26-fold increased risk of death, compared to those ... Read more

October 10, 2017

Gazyva Reduces Risk of Disease Progression in Follicular Lymphoma Patients, Clinical Trial Finds

News

Interim analysis of the GALLIUM (NCT01332968) clinical trial shows that treatment with Gazyva plus chemotherapy improves progression-free survival in patients with advanced, CD20-positive, untreated follicular lymphoma. The GALLIUM trial set ... Read more

September 26, 2017September 26, 2017

European Commission Approves Gazyvaro as First-Line Follicular Lymphoma Therapy

News

The European Commission has approved Roche’s Gazyvaro (obinutuzumab) for previously untreated patients with advanced follicular lymphoma. The treatment is approved in combination with chemotherapy and should be followed by Gazyvaro maintenance therapy. ... Read more

August 30, 2017August 30, 2017

FDA to Review Gazyva as First-Line Treatment for Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental biologics license application (sBLA) seeking the approval of Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone, for patients with previously untreated ... Read more

August 18, 2016August 18, 2016

Gazyva Combination Effective Therapy for NHL Patients Refractory to Rituxan

News

Results from the Phase 3 GADOLIN trial reveal that combining Gazyva (obinutuzumab) with bendamustine (available as Bendeka and Treanda) in patients with indolent non-Hodgkin’s lymphoma who are not responding to ... Read more

July 19, 2016July 19, 2016

Gazyva Plus CHOP Brings No New Benefits to Diffuse Large B-Cell Lymphoma Patients in Phase 3 Study

News

Patients with previously untreated diffuse large B-cell lymphoma (DLBCL) given Gazyva/Gazyvaro (obinutuzumab) plus standard chemotherapy (CHOP) do not have higher progression-free survival rates than those treated with Rituxan/MabThera (rituximab), according to new data ... Read more

March 1, 2016May 13, 2016

FDA Approves Gazyva as Combo Treatment for Follicular Lymphomas Unresponsive to Rituxan

News

Genentech announced that the the U.S. Food and Drug Administration (FDA) has approved the combination of Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva for the treatment of people with follicular lymphoma who were ... Read more

November 9, 2015May 13, 2016

Genentech’s Lymphoma Trial Results to Be Key Focus of ASH Meeting

News

Genentech recently announced that more than 45 abstracts, including eight of its approved or investigational medicines, will be presented during the 57th American Society of Hematology (ASH) Annual Meeting in Orlando, set ... Read more

June 2, 2015August 23, 2016

Genentech’s Therapeutic Strategy for Indolent Non-Hodgkin’s Lymphoma Improves Patients’ Survival

News

Genentech, a member of the Roche Group focused on the treatment of serious or life-threatening medical conditions, recently announced new data on their Phase III GADOLIN trial (NCT01059630) on the ... Read more